JP2004143154A - 点眼剤 - Google Patents
点眼剤 Download PDFInfo
- Publication number
- JP2004143154A JP2004143154A JP2003336240A JP2003336240A JP2004143154A JP 2004143154 A JP2004143154 A JP 2004143154A JP 2003336240 A JP2003336240 A JP 2003336240A JP 2003336240 A JP2003336240 A JP 2003336240A JP 2004143154 A JP2004143154 A JP 2004143154A
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- ketotifen fumarate
- vasoconstrictor
- ophthalmic solution
- edema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002997 ophthalmic solution Substances 0.000 title claims abstract description 9
- 229940054534 ophthalmic solution Drugs 0.000 title claims abstract description 8
- 229960003630 ketotifen fumarate Drugs 0.000 claims abstract description 16
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 claims abstract description 16
- 239000005526 vasoconstrictor agent Substances 0.000 claims abstract description 12
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960002684 aminocaproic acid Drugs 0.000 claims abstract description 9
- 239000003889 eye drop Substances 0.000 claims description 20
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 claims description 5
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 claims description 5
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 claims description 4
- 229960004760 naphazoline hydrochloride Drugs 0.000 claims description 4
- 229960003733 phenylephrine hydrochloride Drugs 0.000 claims description 4
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 229940074774 glycyrrhizinate Drugs 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 2
- 230000003266 anti-allergic effect Effects 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000001629 suppression Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- 206010065334 Mucosal hyperaemia Diseases 0.000 abstract 2
- 206010030111 Oedema mucosal Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 7
- 230000000172 allergic effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000218645 Cedrus Species 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940068988 potassium aspartate Drugs 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical group [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HFWPXARYYXLTQE-UHFFFAOYSA-N [Mg].[K].[K] Chemical compound [Mg].[K].[K] HFWPXARYYXLTQE-UHFFFAOYSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000010624 camphor oil Substances 0.000 description 1
- 229960000411 camphor oil Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 230000002444 effect on eosinophils Effects 0.000 description 1
- 230000001210 effect on neutrophils Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】フマル酸ケトチフェン、血管収縮薬及びε−アミノカプロン酸を配合する点眼剤であり、抗アレルギー作用及び抗炎症作用が増強され、結膜充血、結膜浮腫の抑制が増強された、点眼剤である。
【選択図】 なし
Description
処方 100mL中
フマル酸ケトチフェン 69mg
塩酸テトラヒドロゾリン 50mg
ε−アミノカプロン酸 1000mg
グリセリン 1830mg
滅菌精製水 全量100mL
製造方法
滅菌精製水(95mL)に各成分を溶解して、全量を100mLとした。その後ろ過滅菌を行い、無菌の点眼剤とした。この点眼剤の性状はpH6.1、浸透圧260mOsmであった。
実施例1と同様の製造方法により、表1に示した処方の点眼剤を調製した。
試験方法:実施例1、2、4、7、8及び9の点眼剤と表2に示した比較例1〜4の点眼剤を検体として用いた。スギ花粉を用いて感作したモルモット30匹を、スギ花粉惹起30分後の目のアレルギー症状が均等になるように1群8〜13匹に群分けした。各検体をモルモットの両眼に10μL点眼し、5分後にスギ花粉0.5mg(生食懸濁液10μL)を両目に点眼した。非点眼群は、スギ花粉のみ点眼した。スギ花粉投与後30分後の角結膜の状態を肉眼的に観察した。なお、角結膜の状態の評価はDraize法に準じて、発赤を0〜2の3段階、浮腫を0〜4の5段階、分泌物を0〜3の4段階(トータルスコアー9)でスコアー化した。各状態の評価を下記に示す。このスコアーよりアレルギー症状の改善率(%)を下記式にて算出し、表3に示した。
改善率(%)=100−[(点眼群のトータルスコアーの平均値)/(非点眼群のトータルスコアーの平均値)×100]
発赤
0:充血が全く認められない
1:結膜の一部に充血が認められる
2:結膜全体に充血が認められる
浮腫
0:浮腫が全く認められない
1:結膜の一部に軽い浮腫を認める
2:結膜全体に浮腫が認められる
3:浮腫が角膜の一部を覆っている
4:浮腫が角膜の半分以上を覆っている
分泌物
0:分泌物を認めない
1:明らかな涙液様の分泌物が認められる
2:粘性のある分泌物が認められる
3:分泌物が膜状になり眼瞼を覆っている
Claims (6)
- フマル酸ケトチフェン、血管収縮薬及びε−アミノカプロン酸を配合することを特徴とする点眼剤。
- フマル酸ケトチフェンを0.0138−0.138w/v%配合する請求項1記載の点眼剤。
- 血管収縮薬が、塩酸テトラヒドロゾリン、塩酸ナファゾリン及び塩酸フェニレフリンから選ばれる1種以上である請求項1又は2に記載の点眼剤。
- 血管収縮薬の配合量が、塩酸テトラヒドロゾリンは0.005−0.10w/v%、塩酸ナファゾリンは0.0003−0.006w/v%及び塩酸フェニレフリンは0.01−0.2w/v%である請求項3記載の点眼剤。
- ε−アミノカプロン酸を0.1−5.0w/v%配合する請求項1〜4のいずれかに記載の点眼剤。
- 更にアミノエチルスルホン酸、アスパラギン酸塩及びグリチルリチン酸塩から選ばれる1種以上を配合する請求項1〜5のいずれかに記載の点眼剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003336240A JP2004143154A (ja) | 2002-10-01 | 2003-09-26 | 点眼剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002288407 | 2002-10-01 | ||
JP2003336240A JP2004143154A (ja) | 2002-10-01 | 2003-09-26 | 点眼剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004143154A true JP2004143154A (ja) | 2004-05-20 |
JP2004143154A5 JP2004143154A5 (ja) | 2006-07-06 |
Family
ID=32473330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003336240A Pending JP2004143154A (ja) | 2002-10-01 | 2003-09-26 | 点眼剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2004143154A (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006321787A (ja) * | 2005-04-19 | 2006-11-30 | Daiichi Sankyo Healthcare Co Ltd | フマル酸ケトチフェンを含有する局所粘膜適用医薬組成物 |
JP2010502564A (ja) * | 2006-08-28 | 2010-01-28 | 千寿製薬株式会社 | 眼科用経皮吸収型製剤 |
JP2012144570A (ja) * | 2005-04-19 | 2012-08-02 | Daiichi Sankyo Healthcare Co Ltd | フマル酸ケトチフェンを含有する局所粘膜適用医薬組成物 |
-
2003
- 2003-09-26 JP JP2003336240A patent/JP2004143154A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006321787A (ja) * | 2005-04-19 | 2006-11-30 | Daiichi Sankyo Healthcare Co Ltd | フマル酸ケトチフェンを含有する局所粘膜適用医薬組成物 |
JP2012144570A (ja) * | 2005-04-19 | 2012-08-02 | Daiichi Sankyo Healthcare Co Ltd | フマル酸ケトチフェンを含有する局所粘膜適用医薬組成物 |
JP2010502564A (ja) * | 2006-08-28 | 2010-01-28 | 千寿製薬株式会社 | 眼科用経皮吸収型製剤 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011157388A (ja) | 点眼剤 | |
JP5176132B2 (ja) | 眼科用剤 | |
JP2009161454A (ja) | 眼科用組成物 | |
JP5132015B2 (ja) | 点眼剤組成物 | |
JP2001097865A (ja) | 眼科用組成物 | |
JP4904687B2 (ja) | 眼科用組成物 | |
JPH11189533A (ja) | 点眼薬 | |
JP4849288B2 (ja) | 点眼剤及び涙液膜の安定化剤 | |
JP2004143154A (ja) | 点眼剤 | |
JP2009029779A (ja) | レボカバスチン及び/又はその塩を含有する水性医薬組成物 | |
JP2015067607A (ja) | 複数の成分を配合した点眼剤 | |
JP2005247802A (ja) | 点眼剤 | |
JP5041761B2 (ja) | 眼粘膜適用製剤 | |
JP5500162B2 (ja) | 点眼剤 | |
JP2007169232A (ja) | 眼科用組成物 | |
JP4442118B2 (ja) | 安定な点眼剤 | |
JP4779382B2 (ja) | 点眼剤用組成物 | |
JP2012006962A (ja) | 眼科用組成物 | |
JP2004143157A (ja) | 点眼剤 | |
JP2005008596A (ja) | 眼科用組成物 | |
JP2005247795A (ja) | 安定な点眼剤 | |
JP2002128671A (ja) | 点眼液 | |
JP2004143156A (ja) | 点眼剤 | |
JP4961671B2 (ja) | 点眼剤 | |
JP2004143155A (ja) | 眼科用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060522 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060522 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091117 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100309 |